Author(s): Toffey BA, Rabin M, Kurlan R, Toffey BA, Rabin M, Kurlan R, Toffey BA, Rabin M, Kurlan R, Toffey BA, Rabin M, Kurlan R
Abstract Share this page
Abstract Varenicline (Chantix[R]) is a nicotinic acetylcholine receptor partial agonist used to aid smoking cessation. Adverse psychiatric and behavioral effects of the drug are recognized and national drug monitoring has included reports of tardive dyskinesia, but no cases have been described in the literature. We now report the first two cases of varenicline-related withdrawal emergent dyskinesias.
This article was published in Open Neurol J
and referenced in Pharmaceutical Regulatory Affairs: Open Access